Role of blood transfusion product type and amount in deep vein thrombosis after cardiac surgery

Ghazi, Lama; Schwann, Thomas A.; Engoren, Milo; Habib, Robert H.

doi:10.1016/j.thromres.2015.10.041

Cited by 36 publications

(43 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Although this conference did not consider transfusion requirements as a possible risk factor for postop VTE, transfusion has been linked to an increased risk of VTE in several other clinical populations. 35,36 It has been suggested that the increased risk of VTE following transfusion may not be the result of factors intrinsic to the transfusion itself, but rather due to extrinsic variables related to the patient's condition at the time of the transfusion (anemic, hypovolemic, etc.). EBL was higher in the VTE group than in the normal group (►Table 2) and represented a possible confounder to our findings regarding the effect of the transfusion itself.…”

Section: Discussionmentioning

confidence: 99%

Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction

Sultan

Jackson

Erhard

et al. 2017

J reconstr Microsurg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction

Sultan

Jackson

Erhard

et al. 2017

J reconstr Microsurg

View full text Add to dashboard Cite

show abstract

“…Several other studies have looked at outcomes of multicomponent transfusion in specific patient populations. It has been reported that in cardiac surgery patients, multicomponent transfusion is associated with increased odds of profound vasoplegia, postoperative stroke, and postoperative thromboembolic events, and in liver transplant patients it has been associated with greater odds of acute lung injury . To our knowledge, our study is the first to report on outcomes of in‐hospital mortality, LOS, and discharge location, and for a general hospital population as opposed to a particular patient group.…”

Section: Discussionmentioning

confidence: 88%

“…Some studies have previously reported on the epidemiology of multicomponent transfusion . However, multicomponent transfusion was not their primary focus, and almost a quarter of the studies were published only as conference abstracts, resulting in limited information and detail provided on multicomponent transfusion, which indicates the need for further, more detailed research on this topic.…”

mentioning

confidence: 99%

Trends and outcomes in multicomponent blood transfusion: an 11‐year cohort study of a large multisite academic center

et al. 2019

View full text Add to dashboard Cite

BACKGROUND: Most studies reporting on blood component utilization overlook patients transfused with more than one type of blood product (multicomponent transfusion). These patients are of importance, as they are large consumers of blood products and likely have different characteristics and outcomes than nontransfused patients and patients transfused with only one blood component type. Our study aimed to determine the prevalence of multicomponent transfusion at a large multisite academic center, as well as the patient characteristics and outcomes associated with multicomponent transfusion. METHODS:A retrospective cohort study of transfused adult inpatients at the Ottawa Hospital between 2007 and 2017 was performed. Eligible transfusions were red blood cells (RBCs), platelets, plasma, cryoprecipitate, and/or fibrinogen concentrate. Descriptive analyses were done to determine multicomponent transfusion prevalence. Patient characteristics and outcomes associated with multicomponent transfusion were assessed using multivariable regressions. ABBREVIATIONS: aOR = adjusted odds ratio; FP = frozen plasma; FR = fibrinogen replacement; HOMR = Hospital-Patient One-Year Mortality Risk; LOS = length of stay; OHDW = Ottawa Hospital Data Warehouse; PLTs = platelets; TDM = Transfusion Data Mart.From the * Admissions with transfusions of any one type of blood component within 24 hours but not multicomponent transfusions. † P value from chi-square test, t test, or median test for categorical, continuous, or skewed continuous data, respectively. ‡ Internal medicine other than cardiology. § Surgery other than cardiac, vascular, and orthopedic surgeries. || The HOMR score was unavailable for admissions prior to April 2008; data shown are based on a total sample size of n = 49,889.

show abstract

“…None of the studies reported crude measures of association; only adjusted measures were given, and variables controlled for differed by study and were not reported in three of the studies (Table ). In cardiac surgery patients, multicomponent transfusion was associated with a statistically significant increased odds of developing profound vasoplegia (Alfirevic et al, ), postoperative thromboembolic events (Miyata, ; Ghazi et al, ) and postoperative stroke (Mikkola et al, ) (Table ). Large‐volume co‐transfusions of RBCs and plasma were found to be associated with significantly increased odds of developing acute lung injury following liver transplant (Zhao et al, ) (Table ).…”

Section: Resultsmentioning

confidence: 99%

The epidemiology of multicomponent blood transfusion: a systematic review

Perelman

Khair

Dermer

et al. 2019

Transfusion Medicine

View full text Add to dashboard Cite

We performed a systematic review to describe the prevalence of multicomponent blood transfusion and, as a secondary objective, to determine patient characteristics and outcomes associated with multicomponent transfusion. There is a lack of literature on the epidemiology of multicomponent transfusion as most studies concentrate on a single blood product and its utilisation. Patient care and blood management can be optimised by better understanding the patients who receive multicomponent transfusions. The databases Medline, EMBASE and the Cochrane Library of Systematic Reviews were searched. Observational cohort and cross-sectional studies of hospital patients reporting on multicomponent transfusion prevalence or on patient characteristics and outcomes associated with multicomponent transfusion were included. A descriptive synthesis of studies was performed. A total of 37 eligible studies were included. It was found that multicomponent transfusion prevalence varied greatly by patient population and by the combination of blood products given in the multicomponent transfusion. Multicomponent-transfused patients included burn, cardiac surgery, liver surgery and transplant, cancer, infectious diseases, trauma and intensive care unit patients. Five studies found associations between multicomponent transfusion and adverse health outcomes; however, these findings are likely confounded by indication. The overall quality of evidence was low given a fair-to-poor individual study quality, inconsistent multicomponent transfusion prevalence estimates and confounding by indication. Further research is needed to better understand the epidemiology of multicomponent transfusion, including studies on multicomponent transfusion in haematological cancer patients and studies looking for patient characteristics that can better predict multicomponent transfusion need.

show abstract

Role of blood transfusion product type and amount in deep vein thrombosis after cardiac surgery

Cited by 36 publications

References 32 publications

Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction

Risk Factors for Postoperative Venous Thromboembolic Complications after Microsurgical Breast Reconstruction

Trends and outcomes in multicomponent blood transfusion: an 11‐year cohort study of a large multisite academic center

The epidemiology of multicomponent blood transfusion: a systematic review

Contact Info

Product

Resources

About